首页 | 本学科首页   官方微博 | 高级检索  
检索        


Effect of blocking IGF-Ⅰ receptor on growth of human hepatocellular carcinoma cells
Authors:You-Cheng Zhang  Xiao-Peng Wang  Ling-Yi Zhang  Ai-Lin Song  Zhi-Min Kou  Xu-Sheng Li
Institution:1. Department of Surgery, Lanzhou University Second Hospital, Lanzhou 730030, Gansu Province, China
2. Department of Surgery, Gansu Provincal People's Hospital, Lanzhou 730000, Gansu Province, China
Abstract:AIM: To study the expression level and localization of insulin-like growth factor -Ⅰ receptor (IGF-IR) in HepG2 cells and Chang liver cells, and to observe the effect of anti-IGF-IR monoclonal antibody (αIR3) on the growth of HepG2 cells.METHODS: The expression of IGF-IR in HepG2 cells and Chang liver cells was detected by immunohistochemistry.The influences of αIR3 on proliferation and apoptosis were examined by the 3- (4, 5-dimethylthiazol-2-yl)-2, 5-diphenyltetrazolium bromide (MTT) assay and electron microscopy, respectively. Flow cytometry (FCM) was applied for the analysis of cell cycle and apoptosis was observed under electron microscope.RESULTS: IGF-IR was located in the membranes of both HepG2 and Chang liver cell lines, and the expression level of IGF-IR was higher in HepG2 cells than in Chang liver cells. Treated with 0.1 μg/mL αIR3 for 48 h in vitro, the cell growth index (GI) of HepG2 cells was significantly higher than that of control (103.41% vs 100%, P < 0.01).However, the αIR3 for 24 h at final concentration of 4.0 μg/mL made the GI of HepG2 cells lower than that of control (93.37% vs 100%, P < 0.01). Compared with control, treated with αIR3 for 48 h at final concentrations ranging from 1.0 μg/mL to 4.0 μg/mL markedly reduced the GIs of HepG2 cells (97.63%, 97.16%, 95.13%,92.53% vs 100%, P < 0.05 or P < 0.01), treated with αIR3 for 72 h at final concentrations ranging from 0.2 μg/mL to 4.0 μg/mL decreased the GIs of HepG2 cells obviously (95%, 91.63%, 90.77%, 89.84%, 88.51% vs 100%, P < 0.01), and treated with αIR3 for 96 h at final concentrations ranging from 0.5 μg/mL to 4.0 μg/mL made GIs of HepG2 cells lower significantly (88.86%,83.97%, 79.81%, 77.24%, 70.51% vs 100%, P < 0.05 or ,P < 0.01). Moreover, treated with αIR3 from 24 h to 96 h at final concentrations ranging from 0.2 μg/mL to 4.0 μg/mL reduced the GI of HepG2 cells from 97.63% to 70.51% in a dose- and time-dependent manner. Also,αIR3 treatment for 72 h at final concentration from 0.5 μg/mL to 2.0 μg/mL increased the proportion of G0/G1 phase cells(61.73%, 67.1%, 83.7%,76.87% vs 44.47%,P < 0.01) and significantly decreased that of S phase cells(28.63%, 25.13%, 15.63%, 23.13% vs 53.17%, P < 0.01), in contrast to the proportion of G2/M phase cells.The apoptotic rates of HepG2 cells were increased more than that of control (7.83%, 16.13%, 21.1%, 37.73% vs 4.13%, P < 0.01).CONCLUSION: The malignant cell phenotype of human hepatocarcinoma cell is related to overexpression of IGFIR. The blockage of IGF-IR with αIR3 may contribute to the inhibition of proliferation and induction of apoptosis in HepG2 cells.
Keywords:Insulin-like growth factor  Receptor  Monoclonal antibody  Hepatocellular carcinoma cell  Target therapy
本文献已被 万方数据 等数据库收录!
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号